Development of new basal insulin peglispro (LY2605541) ends in a disappointing result

Lignende værker

• How Can a Good Idea Fail? Basal Insulin Peglispro [LY2605541] for the Treatment of Type 2 Diabetes
  af: Muñoz-Garach, Araceli, et al.
  Udgivet: (2016)
• Pharmacokinetics of the Long‐Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function
  af: Linnebjerg, Helle, et al.
  Udgivet: (2016)
• Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism
  af: Moore, Mary Courtney, et al.
  Udgivet: (2014)
• Open‐label, randomized study comparing basal insulin peglispro and insulin glargine, in combination with oral antihyperglycemic medications, in insulin‐naïve Asian patients with type 2 diabetes
  af: Hirose, Takahisa, et al.
  Udgivet: (2017)
• A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
  af: Bergenstal, Richard M., et al.
  Udgivet: (2012)